ubmslateCN-logo-ubm

CN Mobile Logo

Topics:

Ovarian Cancer

Ovarian Cancer

Low-grade serous ovarian cancer is a rare, slow-growing cancer that is generally resistant to cytotoxic chemotherapy. In the upfront setting, treatment recommendations mimic those of high-grade serous ovarian cancer.

Elevated levels of neopterin were found to be significantly associated with poorer survival outcomes in patients with ovarian cancer.

A large, prospective analysis showed that risk factors for ovarian cancer demonstrate substantial heterogeneity in their associations with histologic subtypes of the disease.

In this video Dr. Odunsi discusses a new study that found that higher T-cell diversity in ovarian cancer is associated with poor overall survival.

Despite hematologic toxicities and port-related adverse events, IP carboplatin plus IV dose-dense paclitaxel appears to be effective in patients with suboptimally debulked epithelial ovarian or primary peritoneal carcinoma.

Baseline quality of life measures predict early cessation of chemotherapy and overall survival in women with platinum-resistant/refractory, recurrent ovarian cancer.

Extending platinum-free interval with pegylated liposomal doxorubicin, topotecan, or gemcitabine does not improve overall survival among patients with recurrent ovarian cancer.

Pages

Subscribe to Ovarian Cancer on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.